EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Studying of anti‐inflammatory and antioxidant effects of tectorigenin in ovalbumin‐induced asthma mice models

Jingning Guo, Yanping Shi, Yujun Wang, Seyyed Shamsadin Athari, Tao Chen iD

The Clinical Respiratory Journal · 2024

DOI: 10.1111/crj.13742 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Jingning Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China. Hauptthemen laut MEDLINE: Asthma, Ovalbumin, Isoflavones, Disease Models, Animal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergic asthma is an important respiratory system problem characterized by airway inflammation, breathlessness, and bronchoconstriction. Allergic asthma and its outcomes are triggered by type 2 allergic immune responses. Tectorigenin is a methoxy‐isoflavone with anti‐inflammatory effects. In this study, we investigated the effects of tectorigenin on the pathophysiology of allergic asthma in an animal model.

Methods

Asthmatic mice were treated with tectorigenin. Then airway hyperresponsiveness (AHR), eosinophil percentage, levels of interleukin (IL)‐33, IL‐25, IL‐13, IL‐5, IL‐4, total and ovalbumin (OVA)‐specific immunoglobulin (Ig)E, and lung histopathology were evaluated.

Result

Tectorigenin significantly (P 〈 0.05) reduced eosinophil infiltration (41 ± 7%) in the broncho‐alveolar lavage fluid (BALF), serum IL‐5 level (41 ± 5, pg/mL), and bronchial and vascular inflammation (scores of 1.3 ± 0.2 and 1.1 ± 0.3, respectively) but had no significant effects on AHR, serum levels of IL‐33, −25, −13, and −4 (403 ± 24, 56 ± 7, 154 ± 11, and 89 ± 6 pg/mL, respectively), total and OVA‐specific IgE (2684 ± 265 and 264 ± 19 ng/mL, respectively), goblet cell hyperplasia, and mucus production.

Conclusion

Tectorigenin could control inflammation and the secretion of inflammatory mediators of asthma, so it can be regarded as a potential antiasthma treatment with the ability to control eosinophilia‐related problems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaOvalbuminIsoflavonesDisease Models, AnimalAntioxidantsAnti-Inflammatory AgentsMice, Inbred BALB CAnimalsMiceImmunoglobulin EBronchoalveolar Lavage FluidFemaleLungCytokines

Stichwörter der Autor:innen

Chinese medicineallergyherbal medicineinflammation

Substanzen

OvalbuminIsoflavonestectorigeninAntioxidantsAnti-Inflammatory AgentsImmunoglobulin ECytokines

Autor:innen und Institutionen

  • Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.
  • Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.

ORCID-Profile: Tao Chen

Zitieren

APA

Guo, J., Shi, Y., Wang, Y., Athari, S. S., & Chen, T. (2024). Studying of anti‐inflammatory and antioxidant effects of tectorigenin in ovalbumin‐induced asthma mice models. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13742

Vancouver

Guo J, Shi Y, Wang Y, Athari SS, Chen T. Studying of anti‐inflammatory and antioxidant effects of tectorigenin in ovalbumin‐induced asthma mice models. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.13742

BibTeX
@article{Guo2024,
  author = {Guo, Jingning and Shi, Yanping and Wang, Yujun and Athari, Seyyed Shamsadin and Chen, Tao},
  title = {Studying of anti‐inflammatory and antioxidant effects of tectorigenin in ovalbumin‐induced asthma mice models},
  journal = {The Clinical Respiratory Journal},
  year = {2024},
  doi = {10.1111/crj.13742}
}
Kostenlos starten →